{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:49:48Z","timestamp":1781617788860,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content> immunotherapy targets <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content> antigens expressed by tumor cells in <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content>. Data on outcome of <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">pSOT<\/jats:styled-content> patients are limited. The aim of the study is to describe our experience with allogeneic, third\u2010party <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content> for the treatment of <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">pSOT<\/jats:styled-content> patients in a single tertiary center. Retrospective review was performed of all <jats:styled-content style=\"fixed-case\">pSOT<\/jats:styled-content> patients who received <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content> was diagnosed using World Health Organization histologic criteria. <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content>s were derived from human leukocyte antigen\u2010typed, <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010seropositive third\u2010party donors, and cryopreserved and maintained by an accredited national blood transfusion service. Ten patients received <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content> for histologically proven <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content> from 1999 to 2016 following liver (n=5), combined intestinal\/liver (n=4), and liver\/kidney (n=1) transplantation. <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content> occurred at median age of 40\u00a0months (range: 12\u2010144) and median post\u2010transplant interval of 8\u00a0months (range: 2\u2010107). Seven had monomorphic, two had polymorphic, and one had Hodgkin\u2010type <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content>. All were of B\u2010cell origin and <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010positive on histology. <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content> achieved an overall remission rate of 80% (8 of 10). Transient adverse effects included fever, tachycardia, and vomiting. None developed graft\u2010versus\u2010host disease or opportunistic infections. <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content> is an effective treatment for <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">pSOT<\/jats:styled-content> patients, with good remission rate and minimal toxicity.<\/jats:p>","DOI":"10.1111\/petr.13133","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T05:52:40Z","timestamp":1517464360000},"source":"Crossref","is-referenced-by-count":50,"title":["Cytotoxic T\u2010lymphocyte therapy for post\u2010transplant lymphoproliferative disorder after solid organ transplantation in children"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4777-0267","authenticated-orcid":false,"given":"Fang Kuan","family":"Chiou","sequence":"first","affiliation":[{"name":"Liver Unit (Including Small Bowel Transplantation) Birmingham Women's and Children's Hospital Foundation NHS Trust  Birmingham UK"},{"name":"Paediatric Gastroenterology KK Women's and Children's Hospital  Singapore City Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue V.","family":"Beath","sequence":"additional","affiliation":[{"name":"Liver Unit (Including Small Bowel Transplantation) Birmingham Women's and Children's Hospital Foundation NHS Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen M.","family":"Wilkie","sequence":"additional","affiliation":[{"name":"Scottish National Blood Transfusion Service The Jack Copland Centre  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Vickers","sequence":"additional","affiliation":[{"name":"Scottish National Blood Transfusion Service Royal Infirmary  Aberdeen UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Morland","sequence":"additional","affiliation":[{"name":"Paediatric Oncology Birmingham Women's and Children's Hospital Foundation NHS Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish L.","family":"Gupte","sequence":"additional","affiliation":[{"name":"Liver Unit (Including Small Bowel Transplantation) Birmingham Women's and Children's Hospital Foundation NHS Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/814973"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00325.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04197.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03893.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1390055"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90994-2"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08160.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318277e344"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00318.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.111"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-063008"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239186"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371971"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021782"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200407000-00007"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13051"},{"key":"e_1_2_10_18_1","first-page":"343","volume-title":"WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03683.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01796.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00854.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01211.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13621"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04206.x"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpetr.13133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.13133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:08:25Z","timestamp":1695503305000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/petr.13133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/petr.13133"],"URL":"https:\/\/doi.org\/10.1111\/petr.13133","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"article-number":"e13133"}}